John P. Schmid - 08 Jun 2021 Form 4 Insider Report for XERIS PHARMACEUTICALS INC

Role
Director
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
08 Jun 2021
Net transactions value
$0
Form type
4
Filing time
08 Jun 2021, 19:08:54 UTC
Next filing
17 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Award $0 +11,228 $0.000000 11,228 08 Jun 2021 Common Stock 11,228 $3.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders.